| Autor: |
Paul Kirschmeier, Daniel J. Hicklin, M. Arshad Siddiqui, Payal R. Sheth, Huadong Tang, Elizabeth Smith, Bohdan Yaremko, Abdul Ponery, Lianzhu Liang, Suining Lee, Seema Tevar, Lissette Nale, Kimberly Gray, Chaoyang Dai, Ming Liu, Andrea D. Basso |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1535-7163.c.6531537 |
| Popis: |
Kinesin spindle protein (KSP) is a mitotic kinesin required for the formation of the bipolar mitotic spindle, and inhibition of this motor protein results in mitotic arrest and cell death. KSP inhibitors show preclinical antitumor activity and are currently undergoing testing in clinical trials. These agents have been dosed intravenously using various dosing schedules. We sought to identify a KSP inhibitor that could be delivered orally and thus provide convenience of dosing as well as the ability to achieve more continuous exposure via the use of dose-dense administration. We discovered SCH 2047069, a potent KSP inhibitor with oral bioavailability across species and the ability to cross the blood-brain barrier. The compound induces mitotic arrest characterized by a monaster spindle and is associated with an increase in histone H3 and mitotic protein monoclonal 2 phosphorylation both in vitro and in vivo. SCH 2047069 showed antitumor activity in a variety of preclinical models as a single agent and in combination with paclitaxel, gemcitabine, or vincristine. Mol Cancer Ther; 9(11); 2993–3002. ©2010 AACR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
